Krystal outlines $400M buyback over 2 years and revises 2026 non-GAAP opex to $155M-$165M
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Krystal Biotech (KRYS) Q3 2026 MANAGEMENT VIEW * “Q3 was another strong Q for Krystal,” and the company “delivered $127.3 million in VYJUVEK revenue…reported diluted earnings of $2.05 a share and ended September with $1.2 billion in cash and investments,”…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe buyback and revised cost guidance may support the stock, though it is a small-to-mid cap company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Board authorized a share repurchase program of up to $400 million to be deployed over 2 years.
- 02VYJUVEK revenue in the third quarter was $127.3 million.
- 03The company ended September with $1.2 billion in cash and investments.
- 04Management revised 2026 non-GAAP operating expenses to $155-165 million.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets